ESMO Veranstaltungen


ESMO 2018

Unsere Veranstaltungen auf dem Europäischen Krebskongress

Presseveranstaltungen

Sie sind vor Ort in München auf dem ESMO? Besuchen Sie doch unsere Veranstaltungen vor Ort. Wir bitten um vorherige Anmeldung über

Penzberg, 18. Oktober 2018, 14:00 - 17:30 Uhr
Pressegespräch: Krebstherapie wird smart - Wie digitale Technologien die Personalisierte Medizin revolutionieren

  • Willkommen im Kompetenzzentrum für Personalisierte Medizin - wo Präzisionsmedizin unsere Mission ist
    Dr. Franziska Mech, Roche Diagnostics GmbH
  • Digitalisierte, personalisierte Medizin: Transformation als Chance
    Dr. Martin Hager, Roche Pharma AG
  • Optimal Cancer Care durch richtungsweisendes Tumorprofiling
    Dr. Benedikt Westphalen, Comprehensive Cancer Center München
  • Live Laboratory Tour
    Dr. Vera Grossmann, Foundation Medicine

Für einen Shuttle von München nach Penzberg und zurück wird gesorgt.

München, 19. Oktober 2018, 8:15 - 10:15 Uhr
Mediabriefing: Not one disease - Next generation healthcare by design

  • Part 1: Latest advances from across our oncology portfolio and our vision for the future - Next generation healthcare by design
  • Part 2: Scientific and pipeline insights open session

Wissenschaftliche Symposien

19. Oktober, 18:00 - 20:00 Uhr, ICM, Room 14b, Messe Munich
Comprehensive genomic profiling: Taking precision medicine from vision to reality

  • From vision to reality: Partnering towards personalised healthcare in oncology
    Niko Andre, Switzerland
  • Foundation Medicine´s role in making personalised healthcare a reality
    Jeffrey Ross, UK
  • Integrating comprehensive genomic profiling into real-world settings
    Rohit Lal, UK
  • Design and clinical impact of innovative comprehensive genomic profiling clinical trials
    Alwin Krämer, Germany
    Rebecca Dent, Singapore
    Rafal Dziadziuszko, Poland
  • Driving the future of personalised healthcare through collaborations
    Dr. Niko Andre, Switzerland
  • Q&A session with all speakers

22. Oktober 2018, 13:00 - 14:30 Uhr, ICM - Room 14b, Messe Munich
How immunotherapy is revolutionising first-line lung cancer care

  • Considering the options with cancer immunotherapy in first-line NSCLC
    Mark A. Socinski, USA
  • Navigating between cancer immunotherapy regimens in non-squamous NSCLC -
    Patient profiles discussion
    Fabrice Barlesi, France
  • Putting it all into perspective: What does this mean for our patients?
    Panel discussion
  • A new era for patients with extensive-stage SCLC: evaluating the evidence
    Martin Reck, Germany
  • What are the clinical considerations for the future treatment decisions in SCLC?
    Panel discussion

22. Oktober 2018, 13:00 - 14:30 Uhr, ICM - Room 1, Messe Munich
Changing the natural history of breast cancer:    
Where are we, and what´s next in HER2-positive and triple-negative disease?  

  • Welcome and introduction
    Peter Schmid, UK
  • Drawing closer to cure for patients with HER2-positive eBC
    Javier Cortés, Spain
  • Shifting paradigms in mTNBC with cancer immunotherapy
    Peter Schmid, UK
  • Future combinations and future biomarkers in mTNBC
    Rebecca Dent, Singapore
  • Panel discussion
  • Summary and outlook
    Peter Schmid, UK

22. Oktober 2018, 18:30 - 20:00 Uhr, ICM - Room 13, Messe Munich  
Innovative targeted therapies in NSCLC and beyond

  • Evolution of targeted therapies
    Tony Mok, Hong Kong
  • Transformational therapy - setting a new standard in ALK+ NSCLC
    Rafal Dziadziuszko, Poland
  • Optimising cancer care in rare mutations
    Leora Horn, USA
  • Innovations in blood-based testing - the way forward
    Tony Mok, Hong Kong
  • Panel discussion

Aktuelles und News